Agios Pharmaceuticals, INC Schedule 13G passive stakes

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5,917,400 shares, representing 9.9% of the outstanding common stock of Agios Pharmaceuticals, Inc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 4.57% of Agios Pharmaceuticals, Inc. common stock as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have jointly filed a Schedule 13G, reporting beneficial ownership of 5.1% of Agios Pharmaceuticals, Inc. common stock.

The Vanguard Group has amended its Schedule 13G, reporting 0% beneficial ownership in Agios Pharmaceuticals Inc due to an internal realignment.

Farallon Capital Management and its affiliates updated their beneficial ownership in Agios Pharmaceuticals, Inc. to 8.8%, reflecting internal management changes within Farallon.

State Street Corporation has reported a 5.3% beneficial ownership stake in Agios Pharmaceuticals Inc., holding 3,108,145 common shares as of December 31, 2025.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have filed an exit notice, reporting zero beneficial ownership in Agios Pharmaceuticals, Inc. common stock.

Paradigm BioCapital Advisors LP and related entities have disclosed a 4.9% beneficial ownership stake in Agios Pharmaceuticals, Inc., totaling 2,873,555 shares.

Paradigm BioCapital Advisors LP and its affiliates have reported a 5.2% beneficial ownership stake in Agios Pharmaceuticals, Inc. through a Schedule 13G filing.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.8% of Agios Pharmaceuticals Inc.'s common stock as of June 30, 2025.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a beneficial ownership of 6.1% in Agios Pharmaceuticals, Inc. common stock.

BB Biotech AG and its subsidiary, Biotech Target N.V., have filed an Amendment No. 12 to their Schedule 13G, indicating they no longer hold a beneficial ownership of 5% or more in Agios Pharmaceuticals, Inc.

BB Biotech AG and its subsidiary Biotech Target N.V. have disclosed a continued beneficial ownership of 6.2% in Agios Pharmaceuticals, Inc. common stock as of December 31, 2024.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing their collective beneficial ownership of up to 9.9% of Agios Pharmaceuticals, Inc.'s common stock as of December 31, 2024, affirming a passive investment strategy.